GILD gets clinical hold lifted quickly after a patient death. So, Big Pharma kills someone, clinical hold is "very short." Small company CYDY gets put on hold for very long time for.... why?

Quote:

---

Gilead Sciences' $225 million bet on Arcellx’s CAR-T cell therapy is back in play after the FDA lifted a clinical hold instigated in the wake of a patient death.

The trial pause has been very short , with the regulator only implementing the hold on the iMMagine-1 study in June. At the time, Arcellx said it believed a contributing factor in the fatality had been “limitations on bridging therapy,” a term for the treatments given in the period between the T cells being removed from a patient’s body and the CAR-T being infused.
https://www.fiercebiotech.com/biotech/fda-lif...ient-death

---